Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Consulting agrmnt
Director departure
Appointed director
CC transcript
Notes underwriting agrmnt
Inv. presentation
|
|
Sarepta Therapeutics, Inc. (SRPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
4
| Chambers Michael Andrew (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Bought 5,947 shares
@ $109.19, valued at
$649.4k
Bought 4,032 shares
@ $109.89, valued at
$443.1k
|
|
| 08/14/2023 |
4
| Chambers Michael Andrew (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Bought 23,686 shares
@ $108.05, valued at
$2.6M
|
|
| 08/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"AMENDMENT NO. 3 TO THE SAREPTA THERAPEUTICS, INC. 2018 EQUITY INCENTIVE Plan WHEREAS, Sarepta Therapeutics, Inc. previously adopted and approved the 2018 Equity Incentive Plan ; WHEREAS, the Plan was previously amended by that certain Amendment No. 1, approved by the Board of Directors of the Company on April 3, 2020 and the Company’s stockholders on June 4, 2020 and that certain Amendment No. 2, approved by the Board on April 5, 2022 and the Company’s stockholders on June 2, 2022; WHEREAS, pursuant to Section 20 of the Plan, the “Administrator” may amend the Plan from time to time subject to Company stockholder approval; and WHEREAS, the Board, as Administrator, has determined that it is in the best interests of the Company and its stockholders to further amend the Plan to i...",
"AMENDMENT NO. 2 TO THE SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN WHEREAS, Sarepta Therapeutics, Inc. previously adopted and approved the Amended and Restated 2013 Employee Stock Purchase Plan ; WHEREAS, the Plan was amended by that certain Amendment No. 1, approved by the stockholders on June 6, 2019; WHEREAS, pursuant to Section 18 of the Plan, the “Administrator” or any of its committees) may amend the Plan from time to time subject to Company stockholder approval; WHEREAS, the Board, as Administrator, has determined that it is in the best interests of the Company and its stockholders to amend the Plan to increase the number of authorized shares under the Plan by 300,000 shares of common stock of the Company, as authorized under the P..." |
|
| 04/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/04/2023 |
4
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 307 shares
@ $136.66, valued at
$42k
|
|
| 03/10/2023 |
4
| Rodino-Klapac Louise (Head of R&D, CSO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 912 shares
@ $153.19, valued at
$139.7k
|
|
| 03/10/2023 |
4
| Estepan Ian Michael (CFO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 744 shares
@ $153.19, valued at
$114k
|
|
| 03/10/2023 |
4
| Brown Ryan Edward (SVP, General Counsel) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 635 shares
@ $153.19, valued at
$97.3k
|
|
| 03/10/2023 |
4
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 314 shares
@ $153.19, valued at
$48.1k
|
|
| 03/08/2023 |
4
| Wigzell Hans Lennart Rudolf (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 186 shares
@ $157.21, valued at
$29.2k
Paid exercise price by delivering 154 shares
@ $157.21, valued at
$24.2k
Granted 4,500 shares
@ $0
Granted 27,000 options to buy
@ $155.99, valued at
$4.2M
|
|
| 03/08/2023 |
4
| BEHRENS M KATHLEEN (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Estepan Ian Michael (CFO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,370 shares
@ $157.21, valued at
$215.4k
Granted 4,500 shares
@ $0
Granted 27,000 options to buy
@ $155.99, valued at
$4.2M
|
|
| 03/08/2023 |
4
| Barry Richard (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Rodino-Klapac Louise (Head of R&D, CSO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,134 shares
@ $157.21, valued at
$178.3k
Granted 4,500 shares
@ $0
Granted 27,000 options to buy
@ $155.99, valued at
$4.2M
|
|
| 03/08/2023 |
4
| Brown Ryan Edward (SVP, General Counsel) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,154 shares
@ $157.21, valued at
$181.4k
Paid exercise price by delivering 171 shares
@ $157.21, valued at
$26.9k
Granted 4,500 shares
@ $0
Granted 27,000 options to buy
@ $155.99, valued at
$4.2M
|
|
| 03/08/2023 |
4
| Chambers Michael Andrew (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Boor Kathryn Jean (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Nicaise Claude (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/08/2023 |
4
| Mayo Stephen (Director) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Granted 1,523 shares
@ $0
Granted 3,257 options to buy
@ $155.99, valued at
$508.1k
|
|
| 03/03/2023 |
4
| Arif Bilal (Chief Tech Ops Officer) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 80 shares
@ $147.57, valued at
$11.8k
Paid exercise price by delivering 172 shares
@ $147.57, valued at
$25.4k
|
|
| 03/03/2023 |
4
| Brown Ryan Edward (SVP, General Counsel) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 196 shares
@ $147.57, valued at
$28.9k
|
|
| 03/03/2023 |
4
| Estepan Ian Michael (CFO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 378 shares
@ $147.57, valued at
$55.8k
|
|
| 03/03/2023 |
4
| Rodino-Klapac Louise (Head of R&D, CSO) has filed a Form 4 on Sarepta Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 522 shares
@ $147.57, valued at
$77k
|
|
| 03/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| SANDS CAPITAL MANAGEMENT, LLC reports a 2.5% stake in Sarepta Therapeutics, Inc. |
|
|
|